<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1870-7203</journal-id>
<journal-title><![CDATA[Acta médica Grupo Ángeles]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd. Grupo Ángeles]]></abbrev-journal-title>
<issn>1870-7203</issn>
<publisher>
<publisher-name><![CDATA[Grupo Ángeles, Servicios de Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1870-72032019000300282</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Síndrome neuroléptico maligno]]></article-title>
<article-title xml:lang="en"><![CDATA[Neuroleptic malignant syndrome]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ortega Chavarría]]></surname>
<given-names><![CDATA[María José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz Greene]]></surname>
<given-names><![CDATA[Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez Weber]]></surname>
<given-names><![CDATA[Federico]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad La Salle Facultad Mexicana de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad La Salle Facultad Mexicana de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad La Salle Facultad Mexicana de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2019</year>
</pub-date>
<volume>17</volume>
<numero>3</numero>
<fpage>282</fpage>
<lpage>286</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1870-72032019000300282&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1870-72032019000300282&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1870-72032019000300282&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: Descrita por primera vez en 1960 por Delay y colaboradores, se trata de una patología de presentación rara, pero potencialmente mortal. Es característica la manifestación de hipertermia, alteración del estado neurológico, rigidez muscular y disautonomía. Es una reacción de idiosincrasia secundaria a la administración de fármacos del grupo de los neurolépticos, se relacionan con más frecuencia los que actúan en los receptores dopaminérgicos tipo 2. El tratamiento consiste en descontinuar el fármaco desencadenante, manejo de soporte hemodinámico y prevención de complicaciones. La mortalidad resulta de las manifestaciones clínicas y las complicaciones sistémicas. Se presenta un caso de paciente femenino con antecedente de trastorno depresivo mayor y trastorno de ansiedad generalizada, ingresa al Servicio de Urgencias con datos sugerentes de síndrome neuroléptico maligno posterior a la ingesta de múltiples medicamentos de forma intencional. Se le admite para vigilancia intrahospitalaria.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Initially described in 1960 by Delay et al; it is a rare but potentially deadly. The presentation of hypothermia, alterations in consciousness levels, muscular rigidity and disautonomy are characteristic. It&#8217;s a secondary idiosyncratic response to the administration of neuroleptics, most frequently related with the administration of medications acting upon type 2 dopaminergic receptors. Treatment consists of discontinuing the drug, hemodynamic support and complication prevention. Mortality results from systemic complications and clinical manifestations. We present a case, a female patient with past medical history of major depressive disorder and generalized anxiety, she is admitted to the emergency room with clinical signs suggestive of malignant neuroleptic syndrome caused by intentional ingestion of multiple drugs; she is admitted to hospital for close monitorization.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Síndrome neuroléptico maligno]]></kwd>
<kwd lng="es"><![CDATA[hipertermia]]></kwd>
<kwd lng="es"><![CDATA[fármacos dopaminérgicos]]></kwd>
<kwd lng="es"><![CDATA[rabdomiólisis]]></kwd>
<kwd lng="en"><![CDATA[Neuroleptic malignant syndrome]]></kwd>
<kwd lng="en"><![CDATA[hyperthermia]]></kwd>
<kwd lng="en"><![CDATA[dopaminergic drugs]]></kwd>
<kwd lng="en"><![CDATA[rhabdomyolysis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caroff]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Mann]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hipertermia y síndrome maligno ocasionado por neurolépticos]]></article-title>
<source><![CDATA[Anesth Clin North Am]]></source>
<year>1994</year>
<volume>3</volume>
<page-range>523-43</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gelenberg]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bellinghausen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wojcik]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Falk]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
<name>
<surname><![CDATA[Sachs]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital]]></article-title>
<source><![CDATA[Am J Psychiatry]]></source>
<year>1988</year>
<volume>145</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>517-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hermesh]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Aizenberg]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lapidot]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Munitz]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of malignant hyperthermia among patients with neuroleptic malignant syndrome and their families]]></article-title>
<source><![CDATA[Am J Psychiatry]]></source>
<year>1988</year>
<volume>145</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1431-4</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adityanjee]]></surname>
</name>
<name>
<surname><![CDATA[Aderibigbe]]></surname>
<given-names><![CDATA[YA]]></given-names>
</name>
<name>
<surname><![CDATA[Mathews]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of neuroleptic malignant syndrome]]></article-title>
<source><![CDATA[Clin Neuropharmacol]]></source>
<year>1999</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>151-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levenson]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuroleptic malignant syndrome]]></article-title>
<source><![CDATA[Am J Psychiatry]]></source>
<year>1985</year>
<volume>142</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1137-45</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nimmo]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
<name>
<surname><![CDATA[Tullett]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
<name>
<surname><![CDATA[Blyth]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Dougall]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug-induced hyperthermia]]></article-title>
<source><![CDATA[Anaesthesia]]></source>
<year>1993</year>
<volume>48</volume>
<page-range>892-5</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velamoor]]></surname>
<given-names><![CDATA[VR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuroleptic malignant syndrome. Recognition, prevention and management]]></article-title>
<source><![CDATA[Drug Saf]]></source>
<year>1998</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>73-82</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caroff]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Mann]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuroleptic malignant syndrome]]></article-title>
<source><![CDATA[Med Clin North Am]]></source>
<year>1993</year>
<volume>77</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>185-202</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keck]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Pope]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[McElroy]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Nierenberg]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors for neuroleptic malignant syndrome. A case-control study]]></article-title>
<source><![CDATA[Arch Gen Psychiatry]]></source>
<year>1989</year>
<volume>46</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>914-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chandran]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mikler]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Keegan]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuroleptic malignant syndrome: case report and discussion]]></article-title>
<source><![CDATA[CMAJ]]></source>
<year>2003</year>
<volume>169</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>439-42</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hayashi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Chihara]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical features of neuroleptic malignant syndrome in basal ganglia disease. Spontaneous presentation in a patient with Hallervorden-Spatz disease in the absence of neuroleptic drugs]]></article-title>
<source><![CDATA[Anaesthesia]]></source>
<year>1993</year>
<volume>48</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>499-502</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Bernstein]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Grande]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<source><![CDATA[Problems in anesthesia]]></source>
<year>1994</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>148-56</page-range><publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[J.B. Lippincott Company]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Addonizio]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Susman]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuroleptic malignant syndrome and use of anesthetic agents]]></article-title>
<source><![CDATA[Am J Psychiatry]]></source>
<year>1986</year>
<volume>143</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>127-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gurrera]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome]]></article-title>
<source><![CDATA[Am J Psychiatry]]></source>
<year>1999</year>
<volume>156</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>169-80</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ebadi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Srinivasan]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders]]></article-title>
<source><![CDATA[Pharmacol Rev]]></source>
<year>1995</year>
<volume>47</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>575-604</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adnet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lestavel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Krivosic-Horber]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuroleptic malignant syndrome]]></article-title>
<source><![CDATA[Br J Anaesth]]></source>
<year>2000</year>
<volume>85</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>129-35</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strawn]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Keck]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Caroff]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuroleptic malignant syndrome]]></article-title>
<source><![CDATA[Am J Psychiatry]]></source>
<year>2007</year>
<volume>164</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>870-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Knorr]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Schöllkopf]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Haen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuroleptic malignant syndrome]]></article-title>
<source><![CDATA[Nervenarzt]]></source>
<year>2018</year>
<volume>89</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>300-10</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berman]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuroleptic malignant syndrome: a review for neurohospitalists]]></article-title>
<source><![CDATA[Neurohospitalist]]></source>
<year>2011</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>41-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsujimoto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Maeda]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sugiyama]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yokochi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chikusa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Maruyama]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of prolonged large-dose dantrolene for severe neuroleptic malignant syndrome]]></article-title>
<source><![CDATA[Anesth Analg]]></source>
<year>1998</year>
<volume>86</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1143-4</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caroff]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Mann]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Keck]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Specific treatment of the neuroleptic malignant syndrome]]></article-title>
<source><![CDATA[Biol Psychiatry]]></source>
<year>1998</year>
<volume>44</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>378-81</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaitini]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fradis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vaida]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Krimerman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Beny]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plasmapheresis in neuroleptic malignant syndrome]]></article-title>
<source><![CDATA[Anaesthesia]]></source>
<year>1997</year>
<volume>52</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>165-8</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Birmes]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Coppin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Schmitt]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lauque]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serotonin syndrome: a brief review]]></article-title>
<source><![CDATA[CMAJ]]></source>
<year>2003</year>
<volume>168</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1439-42</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ener]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Meglathery]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Van Decker]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Gallagher]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serotonin syndrome and other serotonergic disorders]]></article-title>
<source><![CDATA[Pain Med]]></source>
<year>2003</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>63-74</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shalev]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hermesh]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Munitz]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortality from neuroleptic malignant syndrome]]></article-title>
<source><![CDATA[J Clin Psychiatry]]></source>
<year>1989</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>18-25</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Modi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dharaiya]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Schultz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Varelas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuroleptic malignant syndrome: complications, outcomes, and mortality]]></article-title>
<source><![CDATA[Neurocrit Care]]></source>
<year>2016</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>97-103</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
